HOPO 14-1, an Oral Actinide Chelator

Single oral doses of HOPO 14-1 up to 7500 mg were administered without dose-limiting toxicity or serious adverse events in healthy adults. Gastrointestinal tolerability defined the practical single-dose ceiling. These findings establish the first human safety and pharmacokinetic profile of a novel, orally administered actinide chelator and support further clinical evaluation of HOPO 14-1 as a countermeasure for internal radionuclide and heavy metal contamination. Development of a deployable and population-level emergency intervention addresses a long-standing unmet need with important implications for public health preparedness.

Corresponding Authors: Sascha N. Goonewardena, MD, University of Michigan Health, 1150 W Medical Center Dr, Ann Arbor, MI 48109 (sngoonew@med.umich.edu); Polly Y. Chang, PhD, SRI International, 333 Ravenswood Ave, Menlo Park, CA 94025 (polly.chang@sri.com).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.